Related Experiment Video
Updated: Aug 26, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy
Shintarou Kimura1, Misa Ichikawa2, Suzuka Sugawara3
1Environmental Science, StateArt Incorporated, Tokyo, JPN.
Intravenous nicotinamide mononucleotide (NMN) is safe and effective in humans. This study shows intravenous NMN boosts blood NAD+ levels and lowers triglycerides, suggesting benefits for age-related diseases and metabolic health.
Area of Science:
- Biochemistry
- Gerontology
- Clinical Medicine
Background:
- Nicotinamide adenine dinucleotide (NAD+) is crucial for cellular processes and healthy aging.
- Oral nicotinamide mononucleotide (NMN) is known to increase NAD+ levels, but its intravenous administration safety and efficacy are unestablished.
- Age-related diseases are often linked to declining NAD+ levels.
Purpose of the Study:
- To evaluate the safety and efficacy of intravenous NMN administration in healthy human volunteers.
- To determine the impact of intravenous NMN on blood NAD+ levels and metabolic markers.
- To explore potential therapeutic applications of intravenous NMN for metabolic disorders.
Main Methods:
- A safety and efficacy study involving 10 healthy human volunteers.
- Intravenous administration of NMN.
- Monitoring of electrocardiograms, pulse, blood pressure, and metabolic markers (liver, heart, pancreas, kidneys).
- Analysis of blood NAD+ levels and triglyceride (TG) levels.
Main Results:
- Intravenous NMN administration was safe, with no adverse effects on vital signs or organ-specific metabolic markers.
- NMN significantly increased blood NAD+ levels without causing hemolysis (blood cell damage).
- A significant reduction in blood triglyceride (TG) levels was observed post-NMN administration.
Conclusions:
- Intravenous NMN administration is safe and well-tolerated in humans.
- Intravenous NMN effectively boosts NAD+ levels and reduces triglycerides.
- Intravenous NMN shows promise for preventing and treating conditions like fatty liver and diabetes associated with high TG levels.
More Related Videos
07:57Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry
Published on: December 26, 2019
06:38In Ovo Feeding of Commercial Broiler Eggs: An Accurate and Reproducible Method to Affect Muscle Development and Growth
Published on: September 20, 2021
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Role of Reduced Coenzymes NADH and FADH₂
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug Distribution as One-Compartment Model and Elimination by Nonlinear Pharmacokinetics: Overview
For instance, consider the metabolism of sodium salicylate. This compound is metabolized into two distinct substances: a glucuronide and a glycine conjugate. The rate of conjugation depends...
Overview of Nitrogen Metabolism
The largest pool of nitrogen available in the terrestrial ecosystem is gaseous nitrogen (N2) from the air, but this...
Biosynthesis of Nucleic Acids